JP2019512528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512528A5 JP2019512528A5 JP2018550327A JP2018550327A JP2019512528A5 JP 2019512528 A5 JP2019512528 A5 JP 2019512528A5 JP 2018550327 A JP2018550327 A JP 2018550327A JP 2018550327 A JP2018550327 A JP 2018550327A JP 2019512528 A5 JP2019512528 A5 JP 2019512528A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disorder
- composition according
- anxiety
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 208000019901 Anxiety disease Diseases 0.000 claims 10
- 208000020401 Depressive disease Diseases 0.000 claims 10
- 206010016256 fatigue Diseases 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- 208000007415 Anhedonia Diseases 0.000 claims 6
- 206010042458 Suicidal ideation Diseases 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 206010002869 Anxiety symptoms Diseases 0.000 claims 4
- 206010010144 Completed suicide Diseases 0.000 claims 4
- 206010041250 Social phobia Diseases 0.000 claims 4
- 208000019906 panic disease Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 206010054089 Depressive symptom Diseases 0.000 claims 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 3
- 229960003299 ketamine Drugs 0.000 claims 3
- CFBVGSWSOJBYGC-ZYHUDNBSSA-N (2r,6r)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1[C@]1(N)CCC[C@@H](O)C1=O CFBVGSWSOJBYGC-ZYHUDNBSSA-N 0.000 claims 2
- CFBVGSWSOJBYGC-JQWIXIFHSA-N (2s,6s)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(N)CCC[C@H](O)C1=O CFBVGSWSOJBYGC-JQWIXIFHSA-N 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 206010033664 Panic attack Diseases 0.000 claims 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 2
- 208000000810 Separation Anxiety Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000000586 desensitisation Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 238000001671 psychotherapy Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000025874 separation anxiety disease Diseases 0.000 claims 2
- 230000036642 wellbeing Effects 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000010513 Stupor Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000009225 cognitive behavioral therapy Methods 0.000 claims 1
- 238000009226 cognitive therapy Methods 0.000 claims 1
- 238000009228 dialectical behavior therapy Methods 0.000 claims 1
- 230000004424 eye movement Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 238000012958 reprocessing Methods 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313317P | 2016-03-25 | 2016-03-25 | |
| US62/313,317 | 2016-03-25 | ||
| PCT/US2017/024238 WO2017165877A1 (en) | 2016-03-25 | 2017-03-27 | Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post traumatic stress disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512528A JP2019512528A (ja) | 2019-05-16 |
| JP2019512528A5 true JP2019512528A5 (https=) | 2020-05-07 |
Family
ID=58530652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550327A Pending JP2019512528A (ja) | 2016-03-25 | 2017-03-27 | 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190083420A1 (https=) |
| EP (1) | EP3432869A1 (https=) |
| JP (1) | JP2019512528A (https=) |
| CN (1) | CN109475514A (https=) |
| AU (1) | AU2017238858A1 (https=) |
| CA (1) | CA3019012A1 (https=) |
| WO (1) | WO2017165877A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3043785T1 (sl) | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| US11191734B2 (en) | 2015-06-27 | 2021-12-07 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| JP7603368B2 (ja) | 2016-03-25 | 2024-12-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | （２ｒ，６ｒ）－ヒドロキシノルケタミン塩酸塩の結晶形態 |
| WO2017180589A1 (en) * | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
| ES2991544T3 (es) * | 2016-11-30 | 2024-12-04 | Wolfson Philip E | Ketamina para el tratamiento de síntomas relacionados con la menstruación |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| CN110343050B (zh) * | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| AU2019262197B2 (en) | 2018-05-04 | 2024-12-19 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020237748A1 (zh) * | 2019-05-24 | 2020-12-03 | 北京大学深圳研究生院 | 一种长效化合物的制备方法 |
| BR112022005579A2 (pt) * | 2019-11-05 | 2022-06-21 | Claes Thulin | 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1,2,4-triazol-3-il]piridina para uso na prevenção e/ou no tratamento de surmenage em um mamífero |
| CN113125586B (zh) * | 2019-12-31 | 2022-05-24 | 成都百裕制药股份有限公司 | 一种1-[2-(2，4-二甲基-苯硫基)-苯基]哌嗪及其异构体的检测方法 |
| CN112521357B (zh) * | 2020-08-31 | 2021-10-08 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
| US12466785B2 (en) | 2020-08-31 | 2025-11-11 | Shenzhen Ruijian Biotechnology Co., Ltd | Long-acting low-addiction HNK derivative and preparation method therefor |
| WO2022041174A1 (zh) | 2020-08-31 | 2022-03-03 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
| CN112516130B (zh) * | 2020-08-31 | 2022-01-04 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性化合物在制备药物中的应用 |
| CN114524737B (zh) * | 2020-11-23 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种取代的环己酮类化合物 |
| CN114947839B (zh) * | 2022-05-27 | 2025-12-02 | 华东师范大学 | 大脑调控的训练方法、装置及电子设备 |
| CN120736994B (zh) * | 2025-01-26 | 2025-11-18 | 上海东西智荟生物医药有限公司 | 氯胺酮衍生物及其在精神疾病的治疗中的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3904332B1 (en) * | 2011-10-14 | 2024-12-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain |
| WO2014020155A1 (en) * | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
-
2017
- 2017-03-27 CA CA3019012A patent/CA3019012A1/en not_active Abandoned
- 2017-03-27 JP JP2018550327A patent/JP2019512528A/ja active Pending
- 2017-03-27 AU AU2017238858A patent/AU2017238858A1/en not_active Abandoned
- 2017-03-27 EP EP17716697.2A patent/EP3432869A1/en not_active Withdrawn
- 2017-03-27 US US16/088,294 patent/US20190083420A1/en not_active Abandoned
- 2017-03-27 WO PCT/US2017/024238 patent/WO2017165877A1/en not_active Ceased
- 2017-03-27 CN CN201780029039.8A patent/CN109475514A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512528A5 (https=) | ||
| EP3043785B1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| Gong et al. | Clinical manifestations of Parkinson disease and the onset of rapid eye movement sleep behavior disorder | |
| JP2020528075A5 (https=) | ||
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| Lehman | Epidemiology of neurodegeneration in American-style professional football players | |
| EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
| Nowak et al. | Daytime impairment and neurodegeneration in OSAS | |
| BR112015010396A2 (pt) | terapia de combinação | |
| WO2014058979A3 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| ME01629B (me) | Upotreba 3,11 b-cis-dihidrotetrabenazina za tretman simptoma huntington-ove bolesti | |
| Clark et al. | A hypnic hypothesis of Alzheimer's disease | |
| Simnani et al. | Impact of COVID-19 on brain and psychological health, its possible mechanisms, and coping strategies | |
| Ebrahim et al. | REM sleep behavior disorder–psychiatric presentations: a case series from the United Kingdom | |
| CN107456572B (zh) | 完全羧化骨钙素在制备快速抗抑郁药中的应用 | |
| Tang et al. | Topiramate in traumatic brain injury: adverse effects on cognitive function | |
| Habermeyer et al. | Psychosis in a case of schizophrenia and Parkinson’s disease | |
| Luborzewski et al. | Modafinil-induced reversible hyperkinetic nondystonic movement disorder in a patient with major depressive disorder | |
| Richards et al. | 2. Background to ICU sedation and ketamine | |
| McLeod et al. | 30 (11A) The concussion quality of life scale-youth validates and complements the post-concussion symptom inventory on days 3 and 10 post-concussion | |
| Almeida et al. | Patient Preferences And Experiences Of Continuous Positive Airway Pressure And Oral Appliances For The Treatment Of Sleep Apnea: A Qualitative Analysis | |
| Marais | Electroconvulsive therapy |